XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI can be given alone or in combination with androgen deprivation therapy Approval is based…

PARSONS, Kan., April 23, 2024 /PRNewswire/ — The Kansas Proving Grounds at Great Plains Industrial Park, a leading facility for testing and innovation, is proud to announce its partnership with SkyscoutAI Innovations Inc., a pioneer in AI-powered wildfire detection and response using…

NEW YORK, April 23, 2024 /PRNewswire/ — The global radiopharmaceuticals market size is estimated to grow by USD 4612.62 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of almost 10.22% during the forecast period. The prevalence of neurological…